Head and neck cancer refers to a group of cancers that start in the mouth, nose, throat, larynx, sinuses, or salivary glands. The global head and neck cancer drugs market includes various product segments such as targeted therapy drugs, chemotherapy drugs, immunotherapy drugs, and other supportive care drugs that are used in the treatment of head and neck cancers. Targeted therapy drugs consist of drugs that block the ability of cancer cells to grow and spread such as cetuximab, nimotuzumab, and pembrolizumab. The adoption of targeted therapy drugs has increased substantially over the recent past due to their high specificity and fewer side effects as compared to chemotherapy drugs. The global head and neck cancer drugs market is estimated to be valued at US$ 1986.3 Mn in 2023 and is expected to exhibit a CAGR of 8.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increased adoption of targeted therapy drugs is one of the major trends being witnessed in the head and neck cancer drugs market growth. Targeted therapy drugs selectively attack cancer cells while sparing normal cells. They are known to be more effective with fewer side effects compared to chemotherapy. The success rates of targeted drugs have encouraged oncologists to use them as the first line of treatment in many cases. Furthermore, the launch of combination therapies consisting of targeted drugs along with chemotherapy and immunotherapy is expected to boost market growth over the forecast period.
Segment Analysis
Head and Neck Cancer Drugs Market
The global Head and Neck Cancer Drugs Market is dominated by the squamous cell carcinoma sub segment. Squamous cell carcinomas accounts for over 90% of all head and neck cancers. This is because squamous cells are the main cell type found in the mucosal lining of the oral cavity, larynx and pharynx. These areas have higher exposure to risk factors like tobacco and alcohol consumption which increase the chances of developing squamous cell carcinoma.
Key Takeaways
The global Head and Neck Cancer Drugs market is expected to witness high growth over the forecast period of 2023 to 2030.
Regional analysis: North America is currently the dominant region in the Head and Neck Cancer Drugs market and is expected to maintain its leading position over the forecast period as well. This is attributed to factors such as high prevalence of head and neck cancers, strong healthcare infrastructure and increasing government support for cancer research. Asia Pacific is expected to be the fastest growing region owing to large patient pool, rising health awareness, improving healthcare facilities and increasing incidence of head and neck cancers.
Key players operating in the Head and Neck Cancer Drugs market are Johnson & Johnson Services, Inc. (DePuy Synthes), Double Medical Technology Inc., Orthofix Holdings, Inc., Ortho-SUV Ltd., Response Ortho LLC, Smith & Nephew, Stryker Corporation, Zimmer Biomet, Auxein Medical, Acumed, Tasarimmed T?bbi Mamuller San. Tic A.?, Orthopaedic Implant Company (€œOIC€), Gexfix SA, WishBone Medical, Inc., and Matrix Meditech.
Get more insights on this topic: https://www.newsstatix.com/head-and-neck-cancer-drugs-market-share-and-opportunity-analysis/
The global Head and Neck Cancer Drugs/Therapeutics Market was valued at USD 752.5 million in 2016 and is estimated to grow significantly in the coming years owing to the development of cost-effective and innovative Head and Neck Cancer treatments.
Cancers of squamous cells present in the linings of larynx, nose, salivary glands, throat, lips, and mouth cause the Head and Neck Cancers.
The Head and Neck Cancer is amongst the common type of cancers.
The increasing number of Head and Neck Cancer patients and the demand for cost-efficient treatment options are helping the Head and Neck Cancer Drugs/Therapeutics Market to grow with a CAGR of 9.4%.Download Free Sample Report @ https://www.millioninsights.com/industry-reports/head-neck-cancer-drugs-therapeutics-market/request-sampleThe most preferred therapy performed by the surgeons is the surgical therapy combined with the radiation therapy.
Moreover, the present treatment options available for Head and Neck Cancer results in less chances of survival rate.
The treatment for Head and Neck Cancer is a significant challenge for the surgeons since the choice of treatment differs from patient to patient and tumor location.
Head and Neck Cancer Market Research Report: By type (Laryngeal, Pharyngeal, Salivary Gland, Oral Cavity, Nasopharyngeal), by Diagnosis (Blood Test, Endoscopy, others), by Treatment (Chemotherapy, Surgery, Others), by End-User – Global Forecast Till 2027Head and Neck Cancer Market – OverviewThe incidence of cancer has grown rapidly over the past few years at an alarming rate, among which head and neck cancer has a huge chunk.
Reports that evaluate the medical device industry have been made accessible by Market Research Future, which creates reports on several industry verticals that review the market development and prospects.
The market is anticipated to pursue growth strategies with a CAGR of 9.5% in the forecast period.The surge in alcohol and tobacco consumed globally is often cited as a key factor contributing to the head and neck cancers.
Substantial developments seen in the oncology field are expected to improve the treatment methods for this type of cancer and will open up new avenues for market progress in the approaching period.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5798 Segmental AnalysisThe segmentation of the head and neck cancer market is conducted on the basis of the type of head and neck cancer, diagnosis, region, treatment type, and end-user.
Based on the type of head and neck cancer, the market is segmented into laryngeal cancer, salivary gland cancer, pharyngeal cancer, nasopharyngeal cancer, lip and oral cavity cancer, and others.
By end-users, the market is segmented into specialty clinics, hospitals, and ambulatory surgical centers.Detailed Regional Analysis The regional assessment of the head and neck cancer market comprises of regions such as the Americas, Europe, Middle East, Asia Pacific, and Africa.
